Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050423 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3047631 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL13136810 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3050427 | 1.00 | HDAC1 (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL8083819 | 0.92 | HDAC1 (0.66) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL1439834 | 0.89 | LMNA (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL12094873 | 0.89 | LMNA (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL1439835 | 0.89 | LMNA (0.64) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL13178014 | 0.89 | AKR1C3 (0.55) | HDAC1HDAC8HDAC3HDAC4HDAC2 | |
| SCHEMBL3057351 | 0.88 | LMNA (0.55) | HDAC1HDAC8HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | claimed |
| EP-2205563-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2010-07-14 | — | — | EP | claimed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | claimed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-8476255-B2 | Histone deacetylase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-07-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| EP-2205563-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | Orchid Research Laboratories Limited (IN) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047615-A2 | NOVEL HISTONE DEACETYLASE INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222379-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC1 3/4885HDAC8 5/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.